Last reviewed · How we verify
NNC6019-0001
NNC6019-0001 is a glucagon receptor antagonist that blocks glucagon signaling to reduce hepatic glucose production and improve glycemic control.
NNC6019-0001 is a glucagon receptor antagonist that blocks glucagon signaling to reduce hepatic glucose production and improve glycemic control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | NNC6019-0001 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor (GCGR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
The drug selectively antagonizes the glucagon receptor, a G-protein coupled receptor primarily expressed on hepatocytes. By blocking glucagon's effects, it reduces hepatic glucose output, which is elevated in type 2 diabetes. This mechanism complements insulin-based therapies and may offer additional glycemic benefit with a lower hypoglycemia risk.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Elevated liver enzymes
Key clinical trials
- CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (PHASE3)
- A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis (PHASE2)
- A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |